Hemophilia Market Size to Hit USD 24.2 Billion by 2032, Driven by Advancements in Gene Therapy and Innovative Treatment Solutions – SNS Insider
Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...
Medscape12d
Hemophilia A: Gene Therapy a Game Changer
“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...
Taiwan News3d
Global Hemophilia Treatment Market to Reach USD 21.48 Billion by 2033, Driven by Advanced Therapies and Innovative Solutions
Market Valuation Set to Surge from USD 13.23 Billion in 2024 at a CAGR of 5.69% ...
Omaha.com19d
Omaha dog owner seeks clinical trial for hemophilia in chin-poodle mix
When a test determined that Walter had hemophilia, his Omaha owner joined a group seeking to raise $50,000 for a clinical trial of a gene therapy for dogs. Emily Wiley wasn’t looking to take Walter ...
Healthline25d
What Is Hemophilia A?
People with hemophilia A bleed and bruise easily, and their blood takes a long time to form clots. Hemophilia A is a rare, serious condition that has no cure, but is treatable. Hemophilia A is ...
Reuters24d
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...
Yahoo Finance22d
Pfizer stops selling hemophilia gene therapy, citing weak demand
Weak demand for Pfizer’s hemophilia gene therapy Beqvez has led the pharmaceutical company to “cease further development and commercialization” of the one-time treatment, a Pfizer spokesperson ...
Spark Therapeutics, a Philly biotech pioneer, is being restructured amid financial write-downs
The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...
FiercePharma22d
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...
Daily Excelsior12d
Hemophilia Update 2025 Conference: Experts call for disability certificates to patients
Jammu Hemophilia Society, in collaboration with the Department of Paediatrics of Shri Maharaja Gulab Singh (SMGS) Hospital ...
Benzinga.com1mon
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Approved in 2022 by the FDA, Hemgenix is the first gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, have current or historical life ...
Omaha.com19d
Omaha dog owner seeks clinical trial for hemophilia in chin-poodle mix
When a test determined that Walter had hemophilia, his Omaha owner joined a group seeking to raise $50,000 for a clinical trial of a gene therapy for dogs. Emily Wiley wasn’t looking to take ...